TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8597522

Group type: EXPERIMENTAL
Intervention: Intravenous m-CPP (0.08 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2229859

Group type: EXPERIMENTAL
Intervention: Geriatric assessment process in acute hospital care (treatment group)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Usual hospital care (control group)
Number of subjects: 436
Study: 344303

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 61
Study: 29903799

Group type: EXPERIMENTAL
Intervention: Low-friction (LF) bedding
Number of subjects: 221
Study: 27627721

Group type: EXPERIMENTAL
Intervention: Endplate-conformed cage (C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-conformed cage (N)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intact group (I)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Finite Element Model (C)
Number of subjects: 12
Study: 26574751

Group type: EXPERIMENTAL
Intervention: High-pressure, intermittent pneumatic compression (HPIPC) 60 minutes twice daily for 16 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard care consisting of an exercise regimen of walking for 20 minutes twice daily for 16 weeks
Number of subjects: 34
Study: 24404664

Group type: EXPERIMENTAL
Intervention: 5% anerdian III
Number of subjects: 295
Study: 27534056

Group type: EXPERIMENTAL
Intervention: Standard antibiotic therapy and Wobenzym
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard antibiotic therapy
Number of subjects: 90
Study: 18308012

Group type: EXPERIMENTAL
Intervention: New-onset diabetes mellitus (DM)
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: New-onset diabetes mellitus (DM) with AF
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Patients without diabetes mellitus (DM)
Number of subjects: 1298
Study: 15898381

Group type: EXPERIMENTAL
Intervention: Sandblasted metal brackets (SB) bonded with resin-modified glass ionomer cement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group: Mesh-based (no sandblasting) brackets bonded with resin-modified glass ionomer cement (CO)
Number of subjects: 60
Study: 12803576

Group type: EXPERIMENTAL
Intervention: 150 mg of extended-release aspirin (ERASA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 150 mg of plain-formulated aspirin (PFASA)
Number of subjects: 20
Study: 11004139

Group type: EXPERIMENTAL
Intervention: Hypothermic ventricular fibrillation (no-touch technique)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Beating heart revascularization (no-pump technique)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Overall in-hospital mortality rate
Number of subjects: 211
Study: 8927667

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 230
Study: 1800302

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg once daily for first 2 weeks and 10 mg once daily for subsequent 2 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nifedipine 10 mg tid for 4 weeks
Number of subjects: 49
Study: 7055378

Group type: EXPERIMENTAL
Intervention: 70 gms/day amino acids
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 90 gms/day glucose
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 90 gms/day glucose + 70 gms/day amino acids
Number of subjects: 29

Group type: COMPARATOR
Intervention: 90 gms/day glucose (normal subjects)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 70 gms/day amino acids (normal subjects)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No caloric intake (normal subjects)
Number of subjects: 29
Study: 31504399

Group type: EXPERIMENTAL
Intervention: Low-dose rivaroxaban added to aspirin
Number of subjects: 27390

Group type: COMPARATOR
Intervention: Aspirin alone (control)
Number of subjects: 27390
Study: 28134983

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl
Number of subjects: 110

Group type: COMPARATOR
Intervention: 2.5% NaOCl
Number of subjects: 110
Study: 28406103

Group type: EXPERIMENTAL
Intervention: Remote-online case-based learning (RO-CBL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Face-to-face case-based learning (control)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (face-to-face CBL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Focus group responses
Number of subjects: 38
Study: 25325911

Group type: EXPERIMENTAL
Intervention: Endovascular therapy in the fifth protocol (n=46)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Endovascular therapy in the first 4 protocols (n=610)
Number of subjects: 656
Study: 22580220

Group type: EXPERIMENTAL
Intervention: Emotion acceptance
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Emotion suppression
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 94
Study: 19525084

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to improve hypertension control
Number of subjects: 0
Study: 18597599

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (ASF) mouthrinse at 10 ml (ASF-10)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (ASF) mouthrinse at 20 ml (ASF-20)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Essential oils (EO) mouthrinse
Number of subjects: 15

Group type: COMPARATOR
Intervention: Chlorhexidine (CHX) rinse
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 15
Study: 16267959

Group type: EXPERIMENTAL
Intervention: Amodiaquine (30 mg/kg over three days, 10 mg/kg/day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Chloroquine (30 mg/kg over three days, 10 mg/kg/day)
Number of subjects: 119
Study: 12427293

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication-free trial after SSRI treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuation of SSRI treatment
Number of subjects: 0
Study: 11916786

Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 9457946

Group type: EXPERIMENTAL
Intervention: Swim-up technique
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Percoll gradient centrifugation technique
Number of subjects: 363

Group type: COMPARATOR
Intervention: Natural cycles
Number of subjects: 363

Group type: COMPARATOR
Intervention: Clomiphene citrate-stimulated cycles
Number of subjects: 363

Group type: COMPARATOR
Intervention: Gonadotropin-stimulated cycles
Number of subjects: 363

Group type: COMPARATOR
Intervention: Washing, swim-down, refrigeration/heparin techniques
Number of subjects: 363
Study: 7699828

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Sedation (PCS) - 1.0 mg bolus dose of midazolam
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Sedation (PCS) - 1.5 mg bolus dose of midazolam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anesthesiologist-Controlled Sedation (ACS) - 1.5 mg bolus dose of midazolam
Number of subjects: 100
Study: 2624937

Group type: EXPERIMENTAL
Intervention: SSR IUD
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: MLCu250 IUD
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: UCD IUD
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: TCu 220C IUD
Number of subjects: 710
Study: 91251

Group type: COMPARATOR
Intervention: Adriamycin (ADM) alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bleomycin (BLM) alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) combined with local hyperthermia (42-43 degrees C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) combined with local hyperthermia (42-43 degrees C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) combined with local hyperthermia (42-43 degrees C) at 4-month follow-up
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) combined with local hyperthermia (42-43 degrees C) at 4-month follow-up
Number of subjects: 15
Study: 30947763

Group type: EXPERIMENTAL
Intervention: Lifetime prevalence of at least one mood, anxiety or alcohol use disorder
Number of subjects: 6126

Group type: EXPERIMENTAL
Intervention: Major depressive disorder (MDD)
Number of subjects: 6126

Group type: EXPERIMENTAL
Intervention: Alcohol abuse
Number of subjects: 6126

Group type: EXPERIMENTAL
Intervention: Any DSM-IV mental disorders (12-month prevalence)
Number of subjects: 6126

Group type: EXPERIMENTAL
Intervention: Obsessive compulsive disorder (OCD)
Number of subjects: 6126

Group type: EXPERIMENTAL
Intervention: Lifetime prevalence of mental disorders in SMHS 2016
Number of subjects: 6126

Group type: EXPERIMENTAL
Intervention: 12-month prevalence of mental disorders in SMHS 2016
Number of subjects: 6126

Group type: EXPERIMENTAL
Intervention: Lifetime GAD
Number of subjects: 6126

Group type: EXPERIMENTAL
Intervention: 12-month prevalence of GAD
Number of subjects: 6126

Group type: EXPERIMENTAL
Intervention: 12-month prevalence of OCD
Number of subjects: 6126
Study: 27891622

Group type: EXPERIMENTAL
Intervention: afoxolaner/milbemycin oxime chews (1×)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: afoxolaner/milbemycin oxime chews (3×)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: afoxolaner/milbemycin oxime chews (5×)
Number of subjects: 32

Group type: COMPARATOR
Intervention: untreated, sham-dosed control
Number of subjects: 32
Study: 25347141

Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization (ISTM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control leg (CL)
Number of subjects: 11
Study: 23475568

Group type: EXPERIMENTAL
Intervention: Metformin (IR and XR formulations)
Number of subjects: 305
Study: 21094018

Group type: EXPERIMENTAL
Intervention: CNA IPT scores
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: CNA IPT, CSDD, PAS, education
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: MDS pain frequency, CSDD, CNA IPT, CNPI, age
Number of subjects: 326
Study: 19142564

Group type: EXPERIMENTAL
Intervention: Serum albumin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Serum magnesium (Mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Serum ferritin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Serum cholesterol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dietary intake of folate and fiber
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dietary intake of iron, thiamin, riboflavin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dietary intake of omega‐3 fatty acids
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sugar intake
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Food avoidance
Number of subjects: 38
Study: 17275226

Group type: EXPERIMENTAL
Intervention: Black cohosh (160 mg daily)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Multibotanical including black cohosh (200 mg daily)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Multibotanical plus soy diet counseling
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen .625 mg, with or without medroxyprogesterone acetate 2.5mg daily
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 15491248

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 11681821

Group type: EXPERIMENTAL
Intervention: Multivitamins with iron (MV with iron) administered daily for 3 months
Number of subjects: 310

Group type: COMPARATOR
Intervention: Noniron multivitamins (MV without iron) administered daily for 3 months
Number of subjects: 310
Study: 9226158

Group type: EXPERIMENTAL
Intervention: G-CSF (filgrastim) 5 microg/kg/d subcutaneously
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (no growth factor)
Number of subjects: 53
Study: 7957490

Group type: EXPERIMENTAL
Intervention: 0.4 mg sublingual nitroglycerin (NTG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study: 3686222

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Diagnostic discography without enzyme injection)
Number of subjects: 20
Study: 28930874

Group type: EXPERIMENTAL
Intervention: 6 g of fish oil daily for 21 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 27788053

Group type: EXPERIMENTAL
Intervention: 1000 IU/d of cholecalciferol
Number of subjects: 829

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 829
Study: 24787495

Group type: EXPERIMENTAL
Intervention: Sucrose supplementation (2 g/kg body weight)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Artificial sweeteners supplementation
Number of subjects: 22
Study: 22250190

Group type: EXPERIMENTAL
Intervention: 500‐mL pump dispenser
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 125‐mL squeeze bottle dispenser
Number of subjects: 87

Group type: COMPARATOR
Intervention: 50‐mL roll‐on dispenser
Number of subjects: 87
Study: 19879555

Group type: EXPERIMENTAL
Intervention: Topical application
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 97
Study: 18519523

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 16061828

Group type: EXPERIMENTAL
Intervention: Thyroxine suppressive treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Thyroxine withdrawal
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (20 euthyroid individuals)
Number of subjects: 22
Study: 14692208

Group type: EXPERIMENTAL
Intervention: Colgate Total Advanced Fresh toothpaste
Number of subjects: 32

Group type: COMPARATOR
Intervention: Commercial fluoridated breath-freshening dentifrice
Number of subjects: 32
Study: 10879311

Group type: EXPERIMENTAL
Intervention: Triple-antibiotic ointment (polymyxin B-bacitracin-neomycin), applied twice daily for up to 14 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Simple gauze-type dressing, applied twice daily for up to 14 days
Number of subjects: 70
Study: 8636300

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (100 mg, im, weekly) plus levonorgestrel (500 micrograms, orally, daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Testosterone enanthate (100 mg, im, weekly) alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate plus levonorgestrel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Testosterone enanthate alone
Number of subjects: 36
Study: 1466089

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei preparation (BLP), 3 g/day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 6141114

Group type: EXPERIMENTAL
Intervention: Loprazolam (1 mg)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 3553244

Group type: EXPERIMENTAL
Intervention: Gestalt empty chair dialogues designed to be personally relevant and high in affect
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dialogues designed to be personally irrelevant and neutral in affect
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Groups in which strong affect was encouraged, but no dialogues enacted
Number of subjects: 44

Group type: COMPARATOR
Intervention: Attention-placebo
Number of subjects: 44
Study: 29872280

Group type: EXPERIMENTAL
Intervention: Home-based self-care program alone (HB group, n=275)
Number of subjects: 12054

Group type: EXPERIMENTAL
Intervention: Home-based program + weekly class-style session (CS group, n=251)
Number of subjects: 12054

Group type: COMPARATOR
Intervention: Control group (nonintervention regions, n=7,195)
Number of subjects: 12054
Study: 27743205

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of paliperidone palmitate (3-month formulation)
Number of subjects: 651
Study: 26395620

Group type: EXPERIMENTAL
Intervention: Real tDCS (cathode over left and anode over right parietal region) during neurorehabilitation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS during neurorehabilitation
Number of subjects: 30
Study: 23639481

Group type: EXPERIMENTAL
Intervention: Depo-Provera (depo-MPA)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 51
Study: 21178594

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenous infusion)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 15
Study: 18450870

Group type: EXPERIMENTAL
Intervention: Zinc supplementation plus oral rehydration salts
Number of subjects: 180000

Group type: COMPARATOR
Intervention: Oral rehydration salts alone (Control)
Number of subjects: 180000
Study: 16504531

Group type: EXPERIMENTAL
Intervention: On-pump CABG (CPB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 30
Study: 12040966

Group type: EXPERIMENTAL
Intervention: Ruscus extract (Fagorutin Ruscus Kapseln)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 11189407

Group type: EXPERIMENTAL
Intervention: IFN alpha-2b
Number of subjects: 29
Study: 7583751

Group type: EXPERIMENTAL
Intervention: Multimedia campaign promoting public action to help maltreated children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimedia campaign exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimedia campaign regarding alcohol and other drug abuse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimedia campaign regarding at-risk children
Number of subjects: 0
Study: 2517626

Group type: EXPERIMENTAL
Intervention: 41% BCAA solution
Number of subjects: 2

Group type: COMPARATOR
Intervention: 23% BCAA solution
Number of subjects: 2
Study: 605356

Group type: EXPERIMENTAL
Intervention: Propantheline (30 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1-hyoscyamine (0.8 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30096579

Group type: EXPERIMENTAL
Intervention: Education program (6-week duration)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 104
Study: 27418685

Group type: EXPERIMENTAL
Intervention: PAH drug treatment in inoperable CTEPH
Number of subjects: 42

Group type: COMPARATOR
Intervention: PAH drug treatment in operable CTEPH
Number of subjects: 42
Study: 24287500

Group type: EXPERIMENTAL
Intervention: T280M variant (rs3732378)
Number of subjects: 3642

Group type: EXPERIMENTAL
Intervention: rs2853707
Number of subjects: 3642

Group type: EXPERIMENTAL
Intervention: rs12636547
Number of subjects: 3642

Group type: EXPERIMENTAL
Intervention: rs1877563
Number of subjects: 3642

Group type: EXPERIMENTAL
Intervention: rs11715522
Number of subjects: 3642

Group type: EXPERIMENTAL
Intervention: rs2669845
Number of subjects: 3642

Group type: EXPERIMENTAL
Intervention: rs9868689
Number of subjects: 3642
Study: 22764744

Group type: EXPERIMENTAL
Intervention: IB1001 75 IU kg(‐1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: nonacog alfa
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: IB1001
Number of subjects: 32
Study: 20418724

Group type: EXPERIMENTAL
Intervention: Patient-selected treatment partner-assisted therapy (TPA)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 499
Study: 18752863

Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin therapy
Number of subjects: 368
Study: 16043684

Group type: EXPERIMENTAL
Intervention: Culture-positive patients (n = 40)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Culture-negative patients (n = 14)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Controls (n = 243)
Number of subjects: 302
Study: 12511452

Group type: EXPERIMENTAL
Intervention: Breast feeding
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 30% glucose plus pacifier
Number of subjects: 180

Group type: COMPARATOR
Intervention: Held in mother's arms
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (1 ml of sterile water)
Number of subjects: 180
Study: 10493684

Group type: EXPERIMENTAL
Intervention: Non-deteriorated cartilage areas
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Deteriorated cartilage areas
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Serum NO levels in HOA patients
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Serum NO levels in ambulatory HOA patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Serum NO levels in healthy volunteers
Number of subjects: 16
Study: 8941409

Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2) and paclitaxel (135 mg/m2)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Cisplatin (75 mg/m2) and cyclophosphamide (750 mg/m2)
Number of subjects: 386
Study: 1780171

Group type: EXPERIMENTAL
Intervention: Oxamniquine, 30 mg/kg in divided doses; Praziquantel, 40 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of infected schoolchildren (Area S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment of individuals excreting >=800 epg (Area W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment of individuals excreting >=100 epg (Area H)
Number of subjects: 0
Study: 7298119

Group type: EXPERIMENTAL
Intervention: High sodium intake (800 mEq/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low sodium intake (10 mEq/day)
Number of subjects: 8
Study: 30266329

Group type: EXPERIMENTAL
Intervention: aP(PTgen/FHA)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: TdaP(PTgen/FHA)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Tdap (comparator)
Number of subjects: 450
Study: 26395129

Group type: EXPERIMENTAL
Intervention: Purified Shilajit (250 mg twice a day for 90 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24852468

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU) treatment with total fluence of 150-180 J/cm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU) treatment
Number of subjects: 0
Study: 22513659

Group type: EXPERIMENTAL
Intervention: 0.6 g per kg per day alanyl-glutamine
Number of subjects: 174

Group type: COMPARATOR
Intervention: isonitrogenous isocaloric parenteral nutrition
Number of subjects: 174